Literature DB >> 20803212

Recurrent tumefactive demyelination without evidence of multiple sclerosis or brain tumour.

A Häne, M Bargetzi, E Hewer, M Bruehlmeier, A Khamis, U Roelcke.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20803212     DOI： 10.1007/s00415-010-5722-1

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


× No keyword cloud information.
  10 in total

Review 1.  Mechanisms of immune dysfunction in renal cell carcinoma.

Authors:  Ithaar H Derweesh; Charles S Tannenbaum; Patricia A Rayman; James H Finke
Journal:  Cancer Treat Res       Date:  2003

2.  Treatment of steroid-unresponsive tumefactive demyelinating disease with plasma exchange.

Authors:  Yang Mao-Draayer; Steven Braff; William Pendlebury; Hillel Panitch
Journal:  Neurology       Date:  2002-10-08       Impact factor: 9.910

Review 3.  Tumefactive demyelinating lesions: nine cases and a review of the literature.

Authors:  Lei Xia; Song Lin; Zhong-cheng Wang; Shao-wu Li; Li Xu; Jing Wu; Shu-yu Hao; Chuan-chuan Gao
Journal:  Neurosurg Rev       Date:  2009-01-27       Impact factor: 3.042

4.  Large focal tumor-like demyelinating lesions of the brain: intermediate entity between multiple sclerosis and acute disseminated encephalomyelitis? A study of 31 patients.

Authors:  J J Kepes
Journal:  Ann Neurol       Date:  1993-01       Impact factor: 10.422

5.  Can permeability measurements add to blood volume measurements in differentiating tumefactive demyelinating lesions from high grade gliomas using perfusion CT?

Authors:  Rajan Jain; Shehanaz Ellika; Norman L Lehman; Lisa Scarpace; Lonni R Schultz; Jack P Rock; Mark Rosenblum; Tom Mikkelsen
Journal:  J Neurooncol       Date:  2009-10-15       Impact factor: 4.130

6.  Prolonged interval between sentinel pseudotumoral demyelination and development of primary CNS lymphoma.

Authors:  Steven Ng; Helmut Butzkueven; Renate Kalnins; Christopher Rowe
Journal:  J Clin Neurosci       Date:  2007-09-24       Impact factor: 1.961

7.  Tumefactive demyelination.

Authors:  M Y Nadkar; R A Deore; Raminder Singh
Journal:  J Assoc Physicians India       Date:  2008-11

8.  Distinguishing tumefactive demyelinating lesions from glioma or central nervous system lymphoma: added value of unenhanced CT compared with conventional contrast-enhanced MR imaging.

Authors:  Dae Sik Kim; Dong Gyu Na; Keon Ha Kim; Ji-Hoon Kim; Eunhee Kim; Bo La Yun; Kee-Hyun Chang
Journal:  Radiology       Date:  2009-03-04       Impact factor: 11.105

Review 9.  The role of the immune system in myelodysplasia: implications for therapy.

Authors:  Elaine M Sloand; Katayoun Rezvani
Journal:  Semin Hematol       Date:  2008-01       Impact factor: 3.851

10.  Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis.

Authors:  C F Lucchinetti; R H Gavrilova; I Metz; J E Parisi; B W Scheithauer; S Weigand; K Thomsen; J Mandrekar; A Altintas; B J Erickson; F König; C Giannini; H Lassmann; L Linbo; S J Pittock; W Brück
Journal:  Brain       Date:  2008-06-05       Impact factor: 13.501
  10 in total
  8 in total

1.  Progress in multiple sclerosis research in the last year.

Authors:  Daniela Galimberti; Elio Scarpini
Journal:  J Neurol       Date:  2012-06-22       Impact factor: 4.849

2.  Brain pseudo-tumoral inflammatory lesion associated with chronic myelomonocytic leukemia.

Authors:  Bastien Joubert; Virginie Desestret; Sylvain Rheims
Journal:  J Neurooncol       Date:  2013-03-10       Impact factor: 4.130

3.  Tumefactive multiple sclerosis requiring emergent biopsy and histological investigation to confirm the diagnosis: a case report.

Authors:  So Yamada; Shoko Merrit Yamada; Hiroshi Nakaguchi; Mineko Murakami; Katsumi Hoya; Akira Matsuno; Kazuto Yamazaki; Yasuo Ishida
Journal:  J Med Case Rep       Date:  2012-04-06

4.  Myelodysplastic syndrome with progressive multifocal predominantly pontine demyelination.

Authors:  Shamik Bhattacharyya; Janice C Wong; Malak Abedalthagafi; Sarah Wahlster; Henrikas Vaitkevicius
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2015-03-12

5.  Recurrent tumefactive demyelination: An unusual presentation.

Authors:  Amita Bhargava; Guruprasad S Pujar; Basavaraj F Banakar; K Shubhkaran; Jangid Hemant
Journal:  J Pediatr Neurosci       Date:  2015 Jan-Mar

6.  A Case of Relapsing-Remitting Tumefactive Demyelination.

Authors:  Ankur Wadhwa; Atri Chatterjee; Neera Chaudhry; Sanghamitra Laskar; Shishir Chandan
Journal:  Ann Indian Acad Neurol       Date:  2019 Jan-Mar       Impact factor: 1.383

7.  Recurrent tumefactive demyelinating lesions in an elderly woman.

Authors:  Erika L Weil; Mohammad Obadah Nakawah
Journal:  Radiol Case Rep       Date:  2022-09-28

8.  Clinico-radiologic features and therapeutic strategies in tumefactive demyelination: a retrospective analysis of 50 consecutive cases.

Authors:  Aigli G Vakrakou; Dimitrios Tzanetakos; Maria-Eleptheria Evangelopoulos; Theodore Argyrakos; John S Tzartos; Maria Anagnostouli; Elissavet Andreadou; Georgios Koutsis; Georgios Velonakis; Panagiotis Toulas; Elias Gialafos; Antonios Dimitrakopoulos; Erasmia Psimenou; Leonidas Stefanis; Constantinos Kilidireas
Journal:  Ther Adv Neurol Disord       Date:  2021-05-18       Impact factor: 6.570
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.